Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

The Role of Supportive Care in the Management of Myelosuppression in Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.

Challenges in the Management of Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.

Dr Nassar on Treatment Options After Chemoradiation in Unresectable, Stage III, EGFR-Mutated NSCLC

June 20th 2023

Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.

Reuss Reviews the Development of LP-300 in Advanced NSCLC

June 19th 2023

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

Exploring TROP2 Expression in Patients with NSCLC

June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Targeting HER3 in EGFR-Mutant NSCLC

June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

Persistence Is Key to Success

June 15th 2023

Vinay Edlukudige Keshava, MD, shares the story of his fellowship and provides advice on how to best transition to the next step in an oncologic career.

FDA Approves New Drug Application for Oncology Injectable Pemrydi RTU

June 14th 2023

The FDA has approved a 505(b)(2) new drug application for Pemrydi RTU, the first and only ready-to-use presentation of pemetrexed or injection that does not require reconstitution, dilution, or refrigeration

Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

June 10th 2023

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

HER2-Directed Agents in NSCLC

June 9th 2023

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

June 9th 2023

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

Investigators Set Sights on Immunotherapy for Long-Term Disease Control in NSCLC

June 9th 2023

Stephen V. Liu, MD, highlighted the importance of next-generation sequencing in lung cancer, key trials that have shifted the non–small cell lung cancer treatment landscape, and detailed ongoing research at Georgetown University Lombardi Comprehensive Cancer Center.

Majority of US Cancer Centers Report Shortages of Cisplatin/Carboplatin Chemotherapy

June 7th 2023

A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC

June 7th 2023

Sotorasib provided consistent benefit over docetaxel in the majority of key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer enrolled to the phase 3 CodeBreaK 200 trial.

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy

June 6th 2023

The addition of tumor treating fields to standard-of-care immunotherapy or chemotherapy regimens elicited an improvement in overall survival vs SOC therapies alone in patients with metastatic non-small cell lung cancer following progression on or after platinum-based chemotherapy, according to data from the phase 3 LUNAR trial.

Sunvozertinib Demonstrates Antitumor Activity and Tolerability in EGFR Exon 20–mutated NSCLC

June 6th 2023

The novel irreversible EGFR exon 20 insertion inhibitor sunvozertinib demonstrated significant clinical activity and similar safety to prior reports in Chinese patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on prior platinum-based chemotherapy, according to results from the phase 2 WO-KONH6 study.

Pembrolizumab Plus Chemo Does Not Significantly Improve Survival in TKI-resistant, EGFR+ NSCLC

June 6th 2023

The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.

ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung Cancer

June 5th 2023

The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.

Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC

June 5th 2023

Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.

Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC

June 4th 2023

Roy S. Herbst, MD, PhD, discusses findings from the overall survival analysis of the phase 3 ADAURA trial of adjuvant osimertinib in patients with stage IB to IIIA resected non–small cell lung cancer harboring EGFR mutations.